BridgeBio Pharma, Inc. (BBIO) AI Stock Analysis

BridgeBio Pharma, Inc. is at the forefront of discovering, developing, and delivering innovative therapies for a spectrum of genetic diseases. The company boasts a robust pipeline comprising 30 programs that span from early discovery stages to advanced phases of development. Notable drug candidates include AG10 and BBP-265, both small molecule stabilizers of transthyretin (TTR) undergoing Phase 3 clinical trials for TTR amyloidosis-cardiomyopathy (ATTR-CM). Its clinical portfolio also features BBP-831 in Phase 2 for pediatric achondroplasia, BBP-631 in Phase 2 for congenital adrenal hyperplasia, Encaleret in Phase 2 for Autosomal Dominant Hypocalcemia Type 1, and BBP-711 for hyperoxaluria and recurrent kidney stones.

BridgeBio Pharma demonstrated substantial revenue growth over recent periods, generating $502.1M in FY2025, up 126.3% following $221.9M in FY2024 and $9.3M in FY2023. Its 5-year revenue CAGR from FY2020 to FY2025 was 127.4%. Gross margin reached 94.4% in FY2025 after 98.3% in FY2024. However, heavy research and development spending of $477.5M in FY2025 contributed to an operating margin of -113.3% and a net loss of -$729.3M, or -$3.60 per share. For the trailing twelve months ended June 30, 2026, revenue totaled $713.1M with quarterly revenue growth of 120.4%, an operating margin of -43.9%, and an eps of -$3.56.

As of June 30, 2026, BridgeBio Pharma held $720.2M in cash and short-term investments against total debt of $2.49B, resulting in net debt of $1.77B. Total assets stood at $1.22B while shareholders' equity was -$2.52B, reflecting negative equity, alongside a current ratio of 1.23. Cash flow remained negative in FY2025, with an operating cash flow of -$445.9M and free cash flow of -$447.0M. During FY2025, capital expenditures were $1.1M and share buybacks totaled $48.3M, while share count increased 34.8% over 5 years.

At a last close of $66.39 on October 16, 2026, BridgeBio Pharma holds a market cap of $12.98B and an enterprise value of $14.62B. The stock trades at a price-to-sales ratio of 18.2x and an EV to revenue multiple of 20.5x, well above the US-listed Healthcare peers median price-to-sales ratio of 4.1x. Its price-to-book ratio is 123.7x. Over the past year, BBIO rose 20.6%, outpacing the S&P 500 return of 16.8%. However, its 5-year return of 38.4% trails the 83.0% gain of the S&P 500, alongside a year-to-date return of -13.2%.

Wall Street coverage shows 15 Strong Buy, 6 Buy, and 2 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target of $108.27 implies upside of 63.1% from the last close of $66.39. For the current fiscal year ending December 31, 2026, consensus estimates model revenue of $1.03B and an eps estimate of -$2.60. For the next fiscal year, 7 analysts project revenue to reach $1.70B, representing 64.0% growth, with an eps estimate of -$0.26. Over the trailing 4 quarters, BridgeBio Pharma produced 1 eps beat, with the next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of BridgeBio Pharma, Inc. (BBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BBIO income statement, BBIO balance sheet, BBIO key metrics, BBIO analyst forecast, BBIO chart. See the BBIO stock overview for the latest quote and news.